These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9148861)

  • 41. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.
    El-Etreby NM; Ghazy AA; Rashad R
    J Ovarian Res; 2017 Apr; 10(1):28. PubMed ID: 28427435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway.
    Wang X; Gui L; Zhang Y; Zhang J; Shi J; Xu G
    Int J Oncol; 2014 Apr; 44(4):1099-106. PubMed ID: 24452274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transforming growth factor-beta isoform expression in human ovarian tumours.
    Bartlett JM; Langdon SP; Scott WN; Love SB; Miller EP; Katsaros D; Smyth JF; Miller WR
    Eur J Cancer; 1997 Dec; 33(14):2397-403. PubMed ID: 9616289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression and significance of transforming growth factor-β1 in epithelial ovarian cancer and its extracellular matrix.
    Chen K; Wei H; Ling S; Yi C
    Oncol Lett; 2014 Nov; 8(5):2171-2174. PubMed ID: 25295105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity.
    Zeinoun Z; Teugels E; Vermeij J; Neyns B; Birrer M; De Grève J
    Cancer Detect Prev; 2003; 27(5):380-8. PubMed ID: 14585325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitation of TGF-beta1 mRNA in porcine mesangial cells by comparative kinetic RT/PCR: comparison with ribonuclease protection assay and in situ hybridization.
    Ceol M; Forino M; Gambaro G; Sauer U; Schleicher ED; D'Angelo A; Anglani F
    J Clin Lab Anal; 2001; 15(4):215-22. PubMed ID: 11436205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-beta1.
    Kitagawa K; Murata A; Matsuura N; Tohya K; Takaichi S; Monden M; Inoue M
    Int J Cancer; 1996 Mar; 66(1):91-7. PubMed ID: 8608973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells.
    Bartlett JM; Rabiasz GJ; Scott WN; Langdon SP; Smyth JF; Miller WR
    Br J Cancer; 1992 May; 65(5):655-60. PubMed ID: 1586592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in reverse transcription polymerase chain reaction analysis of cellular mRNA levels of transforming growth factor-beta1 by capillary electrophoresis with laser-induced fluorescence detection.
    Beck A; Lehmann R; Gambaro G; Häring HU; Schleicher ED; Voelter W; Ceol M
    Clin Chem Lab Med; 1999 May; 37(5):527-32. PubMed ID: 10418743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours.
    Wilson KE; Langdon SP; Lessells AM; Miller WR
    Br J Cancer; 1996 Oct; 74(7):999-1004. PubMed ID: 8855965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.
    Kacinski BM; Carter D; Kohorn EI; Mittal K; Bloodgood RS; Donahue J; Kramer CA; Fischer D; Edwards R; Chambers SK
    Yale J Biol Med; 1989; 62(4):379-92. PubMed ID: 2556864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas.
    Marmé A; Zimmermann HP; Moldenhauer G; Schorpp-Kistner M; Müller C; Keberlein O; Giersch A; Kretschmer J; Seib B; Spiess E; Hunziker A; Merchán F; Möller P; Hahn U; Kurek R; Marmé F; Bastert G; Wallwiener D; Ponstingl H
    Int J Cancer; 2008 Nov; 123(9):2048-56. PubMed ID: 18709643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SNP detection in transforming growth factor-beta1 gene using bacterial magnetic particles.
    Ota H; Takeyama H; Nakayama H; Katoh T; Matsunaga T
    Biosens Bioelectron; 2003 May; 18(5-6):683-7. PubMed ID: 12706579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transforming growth factor-beta (TGF-beta) in human milk.
    Saito S; Yoshida M; Ichijo M; Ishizaka S; Tsujii T
    Clin Exp Immunol; 1993 Oct; 94(1):220-4. PubMed ID: 8403511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A study of the expression of MDR1 gene in solid tumors. Initial results of a multicenter evaluation].
    Chevillard S; Vielh P; Vallidire P; Robert J; Marie JP
    Bull Cancer; 1996 Aug; 83(8):626-33. PubMed ID: 8869042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinct tumor specific expression of TGFB4 (ebaf)*, a novel human gene of the TGF-beta superfamily.
    Tabibzadeh S; Kothapalli R; Buyuksal I
    Front Biosci; 1997 Jul; 2():a18-25. PubMed ID: 9230066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components.
    Wolf NG; Abdul-Karim FW; Schork NJ; Schwartz S
    Am J Pathol; 1996 Aug; 149(2):511-20. PubMed ID: 8701990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transforming growth factor-beta1 in hemangioma of the ovary.
    Loverro G; Cormio G; Perlino E; Vicino M; Cazzolla A; Selvaggi L
    Gynecol Obstet Invest; 1998; 46(3):210-3. PubMed ID: 9736807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of molecular aberrations in ovarian cancer allows novel target identification.
    Cheng KW; Lahad JP; Mills GB
    J Obstet Gynaecol Can; 2004 May; 26(5):461-74. PubMed ID: 15151733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Will molecular biology provide oncologists with information useful for risk assessment, prognosis, or therapeutic decisions in cancer patients?
    Head JF
    Cancer Invest; 1996; 14(6):635-6. PubMed ID: 8951366
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.